alphaveKREBSBIO₹61.00

Krebs Biochemicals and Industries Limited

₹ CrorePeersALPA BALPHARMA VINEETLAB NATCAPSUQ BIOFILCHEM NECLIFE MANGALAM AAREYDRUGSMcap ₹132 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Non-current Assets
+ Property, Plant & Equipment	149.3	145.2	141.4	141.4
+ Capital Work-in-Progress	0.2	1.2	1.6	1.6
+ Other Intangibles	0.7	0.5	0.3	0.3
+ Intangibles under Development	1.8	1.8	0.0	0.0
+ Long-term Loans	2.5	2.9	2.7	2.7
+ Other Non-current Financial Assets	6.2	7.1	7.6	7.6
Non-current Financial Assets	8.8	10.0	10.3	10.3
Total Non-current Assets	160.7	158.8	153.6	153.6
Current Assets
+ Inventories	9.8	6.0	5.7	5.7
+ Trade Receivables	1.9	0.1	0.0	0.0
+ Cash & Cash Equivalents	0.1	0.1	0.1	0.1
+ Short-term Loans	3.0	0.2	0.2	0.2
+ Other Current Financial Assets	2.6	3.8	3.6	3.6
Current Financial Assets	7.6	4.2	3.9	3.9
Total Current Assets	17.4	10.3	9.6	9.6
Total Assets	178.2	169.0	163.2	163.2
Equity
+ Equity Share Capital	21.6	21.6	21.6	21.6
+ Other Equity / Reserves	-140.8	-167.8	-184.3	-184.3
Equity — Owners of Parent	-119.2	-146.2	-162.8	-162.8
Total Equity	-119.2	-146.2	-162.8	-162.8
Liabilities
+ Borrowings — Non-current	183.5	161.3	163.6	163.6
+ Other Non-current Financial Liab	4.0	2.4	1.6	1.6
Non-current Financial Liabilities	187.5	163.7	165.2	165.2
+ Provisions — Non-current	3.1	3.1	2.8	2.8
+ Other Non-current Liabilities	45.0	45.0	45.0	45.0
Non-current Liabilities	235.6	211.7	212.9	212.9
+ Borrowings — Current	9.9	51.0	61.3	61.3
+ Trade Payables	19.0	18.2	13.8	13.8
+ Other Current Financial Liab	14.0	18.2	22.4	22.4
Current Financial Liabilities	42.9	87.3	97.4	97.4
+ Provisions — Current	1.1	0.8	0.7	0.7
+ Other Current Liabilities	17.9	15.5	14.9	14.9
Current Liabilities	61.8	103.5	113.1	113.1
Total Liabilities	297.4	315.3	326.0	326.0
Total Equity & Liabilities	178.2	169.0	163.2	163.2
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	1.3	1.2	1.2
+ Dues to Other Creditors — Current	—	16.9	12.6	12.6

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.